In patients with chronic hepatitis C, ribavirin doses of vitamin D and alpha -2 pegeuinteoperon impact on response to treatment A: randomized, multicenter, phase IV clinical public

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0000152

Enrollment

222

Registered

2011-07-26

Start date

2011-08-01

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Others : control: Interferon + ribavirin (24/48 weeks), the standard treatment (treatment recommendation guidelines) used, depending on the amount and duration ? experimental group: interferon + rib

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Men and women age 20 to 75 years (2) HCV-RNA PCR positive for a (quantitative examination> 50 IU / mL) (3) within the past year, the visual inspection undertaken between (liver imaging) excludes from the hepatocellular carcinoma cases (tabyeongwoneseo conducted if test results are acceptable) (4) If normal pretreatment serum calcium concentration

Exclusion criteria

Exclusion criteria: 1) factors of HCC diagnosis, or treatment (more than six months after treatment, but recurrence of liver cancer if not included) (2) decompensated cirrhosis (non-decompensated liver function boyineunja) (3) the absolute hojunggusu 50,000 cells/mm3 (4) in screening serum creatinine> 1.5 x normal upper limit (5) a history of severe mental illness, particularly depression, major depression, severe mental illness or mental illness, suicide attempts, hospitalization for mental illness or mental disability, due to the mean over a period of time. (6) bugapseongseon disease (7) prescription drugs that are not well controlled by the thyroid (8) HBV or HIV infected people diagnosed concurrent (9), hepatocellular carcinoma treated with non-malignant character than two (2) years after the decision is not no cure Now (10) and other clinical trials, when the head judge to perform the clinical trials, patients that are considered difficult to

Design outcomes

Primary

Measure	Time frame
Sustained viral response rate	—

Secondary

Measure	Time frame
Rapid virologic response rate, RVR;Early virologic response rate, EVR;End of treatment response rate, ETR	—

Countries

Korea, Republic of

Contacts

Public ContactJung-Min Cho

Hanyang University Seoul Hospital

Outcome results